Epicriptina

Epicriptina Uses, Dosage, Side Effects, Food Interaction and all others data.

Epicriptina is also known as beta-dihydroergocryptine presents a molecular formula of 9,10 alpha-dihydro-13'-epi-b-ergocryptine. Together with the alpha-dihydroergocryptine, it represents one-third of the ergoloid mesylate mixture. Epicriptina differs from the alpha form on the position of one methyl group. To know more about the mixture please visit Ergoloid mesylate

Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.

Epicriptina
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Epicriptina
Generic	Epicriptine
Epicriptine Other Names	dihydro-beta-ergocryptine, Epicriptina, Epicriptine, Epicriptinum, Epicryptine
Type
Formula	C₃₂H₄₃N₅O₅
Weight	Average: 577.726 Monoisotopic: 577.326419505
Protein binding	Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Epicriptina is a nootropic with an unknown mechanism of action indicated in individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity.

Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.

Epicriptina is also used to associated treatment for these conditions: No primary neurologial disease, idiopathic decreased mental activity

How Epicriptina works

Epicriptina effect is mainly due to the agonistic activity on dopamine receptor. This activity is categorized as part of the ergoline class which is defined as a producer of a vasoconstrictive effect. Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.